Correlation Between Stayble Therapeutics and Prostatype Genomics

Can any of the company-specific risk be diversified away by investing in both Stayble Therapeutics and Prostatype Genomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Stayble Therapeutics and Prostatype Genomics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Stayble Therapeutics AB and Prostatype Genomics AB, you can compare the effects of market volatilities on Stayble Therapeutics and Prostatype Genomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Stayble Therapeutics with a short position of Prostatype Genomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Stayble Therapeutics and Prostatype Genomics.

Diversification Opportunities for Stayble Therapeutics and Prostatype Genomics

0.79

Correlation Coefficient

Stayble Therapeutics  Prostatype Genomics

Poor diversification

The 3 months correlation between Stayble and Prostatype is 0.79. Overlapping area represents the amount of risk that can be diversified away by holding Stayble Therapeutics AB and Prostatype Genomics AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Prostatype Genomics and Stayble Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Stayble Therapeutics AB are associated (or correlated) with Prostatype Genomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Prostatype Genomics has no effect on the direction of Stayble Therapeutics i.e., Stayble Therapeutics and Prostatype Genomics go up and down completely randomly.

Pair Corralation between Stayble Therapeutics and Prostatype Genomics

Assuming the 90 days trading horizon Stayble Therapeutics AB is expected to generate 0.72 times more return on investment than Prostatype Genomics. However, Stayble Therapeutics AB is 1.39 times less risky than Prostatype Genomics. It trades about -0.09 of its potential returns per unit of risk. Prostatype Genomics AB is currently generating about -0.09 per unit of risk. If you would invest  41.00  in Stayble Therapeutics AB on July 8, 2025 and sell it today you would lose (13.00) from holding Stayble Therapeutics AB or give up 31.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Stayble Therapeutics AB  vs.  Prostatype Genomics AB

Stayble Therapeutics

Risk-Adjusted Performance

Weakest

Over the last 90 days Stayble Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in November 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Prostatype Genomics

Risk-Adjusted Performance

Weakest

Over the last 90 days Prostatype Genomics AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in November 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Stayble Therapeutics and Prostatype Genomics

The main advantage of trading using opposite Stayble Therapeutics and Prostatype Genomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Stayble Therapeutics position performs unexpectedly, Prostatype Genomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prostatype Genomics will offset losses from the drop in Prostatype Genomics' long position.

The idea behind Stayble Therapeutics AB and Prostatype Genomics AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.